Skip to main content
SpringerLink
Log in

An Overview of Medications for Lower Urinary Tract Dysfunction

  • Chapter
Urogynecology in Primary Care

  • 706 Accesses

Abstract

In the last several years, multiple new “bladder medications” have received approval by the Food and Drug Administration. Most of these drugs are designed to treat patients suffering from detrusor overactivity. This chapter will review both old and new pharmacologic treatments for detrusor overactivity and stress urinary incontinence. This chapter will not offer a comprehensive review, but instead will focus on the practical advantages and disadvantages of the most commonly used medications. Before using the drugs mentioned in this chapter, practitioners should familiarize themselves in detail with the relevant clinical pharmacology.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 59.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 79.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Urinary Incontinence Guideline Panel. Urinary Incontinence in Adults: Clinical Practice Guideline. AHCPR Pub. No. 920038. Rockville, MD. Agency for Health Care Policy and Research, Public Health Service, U.S. Department of Health and Human Services. March 1992.

    Google Scholar 

  2. Clinical Evidence Issue 10. December 2003. BMJ Publishing Group, London.

    Google Scholar 

  3. Dmochowski RR, Miklos JR, Norton PA, Zinner NR, Yalcin I, Bump RC. Duloxetine versus placebo for the treatment of North American women with stress urinary incontinence. J Urol. 2003;170:1259–1263.

    Article  PubMed  CAS  Google Scholar 

  4. van Kerrebroeck P, Abrams P, Lange R, et al. Duloxetine versus placebo in the treatment of European and Canadian women with stress urinary incontinence. BJOG. 2004;111:249–257.

    Article  PubMed  CAS  Google Scholar 

  5. Norton PA, Zinner NR, Yalcin I, Bump RC. Duloxetine versus placebo in the treatment of stress urinary incontinence. Am J Obstet Gynecol. 2002; 187:40–48.

    Article  PubMed  CAS  Google Scholar 

  6. Thuroff J, Chartier-Kastler E, Corcus J, et al. Medical treatment and medical side effects in urinary incontinence in the elderly. World J Urol. 1998;16:548–561.

    Article  Google Scholar 

  7. Davila GW, Daugherty CA, Sanders SW; Transdermal Oxybutynin Study Group. A short-term, multicenter, randomized double-blind dose titration study of the efficacy and anticholinergic side effects of transdermal compared to immediate release oral oxybutynin treatment of patients with urge urinary incontinence. J Urol. 2001;166:140–145.

    Article  PubMed  CAS  Google Scholar 

  8. Nilvebrant L, Sundquist S, Gillberg PG. Tolterodine is not subtype (m1-m5) selective but exhibits functional bladder selectivity in vivo. Neurourol Urodyn. 1996;15:310–311.

    Google Scholar 

  9. Diokno AC, Appell RA, Sand PK, et al. Prospective, randomized, double-blind study of the efficacy and tolerability of the extended-release formulation of oxybutynin and tolterodine for overactive bladder: results of the OPERA trial. Mayo Clin Proc. 2003; 78:687–695.

    PubMed  CAS  Google Scholar 

  10. Appell RA, Chancellor MB, Zohrist RH, Thomas H, Sanders SW. Pharmacokinetics, metabolism and saliva output during transdermal and extended-release oral oxybutynin administration in healthy subjects. Mayo Clin Proc. 2003;78:696–702.

    Article  PubMed  CAS  Google Scholar 

  11. Zinner N, Gittelman M, Harris R, et al. Trospium chloride improves overactive bladder symptoms: a multicenter phase III trial. J Urol. 2004;171:2311–2315.

    Article  PubMed  CAS  Google Scholar 

  12. Haab F, Stewart L, Dwyer P. Darifenacin, an M3 selective receptor antagonist, is an effective and well-tolerated once-daily treatment for overactive bladder. Eur Urol. 2004;45:420–429.

    Article  PubMed  CAS  Google Scholar 

  13. Kuipers ME, Krauwinkel WJ, Mulder H, Visser N. Solifenacin demonstrates high absolute bioavailability in healthy men. Drugs R D. 2004;5:73–81.

    Article  PubMed  CAS  Google Scholar 

  14. Chapple CR, Martinez-Garcia R, Selvaggi L, et al.: for the STAR study group. A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial. Eur Urol. 2005;48:464–470.

    PubMed  CAS  Google Scholar 

Download references

Authors
  1. Patrick J. Culligan
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Division of Urogynecology and Reconstructive Pelvic Surgery, Atlantic Health System, Morristown, NJ, USA

    Patrick J. Culligan MD (Director, Clinical Associate Professor of Obstetrics and Gynecology) (Director, Clinical Associate Professor of Obstetrics and Gynecology)

  2. UMDNJ, Newark, NJ, USA

    Patrick J. Culligan MD (Director, Clinical Associate Professor of Obstetrics and Gynecology) (Director, Clinical Associate Professor of Obstetrics and Gynecology)

  3. Evanston Continence Center, Evanston, IL, USA

    Roger P. Goldberg MD, MPH (Director of Urogynecology Research, Assistant Professor of Obstetrics and Gynecology) (Director of Urogynecology Research, Assistant Professor of Obstetrics and Gynecology)

  4. Northwestern University Medical School, Evanston, IL, USA

    Roger P. Goldberg MD, MPH (Director of Urogynecology Research, Assistant Professor of Obstetrics and Gynecology) (Director of Urogynecology Research, Assistant Professor of Obstetrics and Gynecology)

Rights and permissions

Reprints and permissions

Copyright information

© 2007 Springer-Verlag London Limited

About this chapter

Cite this chapter

Culligan, P.J. (2007). An Overview of Medications for Lower Urinary Tract Dysfunction. In: Culligan, P.J., Goldberg, R.P. (eds) Urogynecology in Primary Care. Springer, London. https://doi.org/10.1007/978-1-84628-167-9_7

Download citation

  • DOI: https://doi.org/10.1007/978-1-84628-167-9_7

  • Publisher Name: Springer, London

  • Print ISBN: 978-1-84628-166-2

  • Online ISBN: 978-1-84628-167-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation